Skip to main content
Cannabinoid Clinical Logo

Main navigation

  • Cannabinoid Science
  • THC VS CBD
  • FDA Difference
  • Resources
  • Covering Cannabinoids
SIGN UP
GLOSSARY

Covering Cannabinoids image – extracting the critical for payers, policy makers and healthcare professionals

CURRENT EDITION, Volume 5

PRINT VERSION

Featured

Revisiting the Implications of the 2018 Farm Bill on Cannabis-Based Products

READ FULL ARTICLE
For Payers

Dispelling the Myths that Impede Patient Care

READ FULL ARTICLE
For Healthcare Providers

Putting Healthcare Providers Back in the Driver’s Seat

READ FULL ARTICLE
For Policymakers

Bringing Clarity to Cannabis-based Product Conundrums

READ FULL ARTICLE
GLOSSARY icon/caret_left Created with Sketch.

Glossary

Title Content
Agricultural Improvement Act of 2018
Bioaccessibility
Bioaccumulation
Botanical Drug Product
Broad Spectrum*
Cannabinoid Receptors
Cannabinoids
Cannabis
Cannabis Halo Effect
Cannabis sativa L.
CBD Oil/Hemp CBD Oil*
Dietary Supplement
Drug Enforcement Administration (DEA) Drug Scheduling
Endocannabinoid System & Receptors
Endocannabinoids
Entourage Effect*
FDA-Approved Formulations of Cannabinoids
FDA-Approved Medication
Full Spectrum*
Hemp
Hemp Oil/Hempseed Oil*
Isolate*
Marijuana
Medical Cannabis*
Nutraceutical*
Phytocannabinoids
Phytoremediation
Pyramid of Evidence
Real-World Evidence
Recreational Marijuana*
Synthetic Cannabinoids
Terpenes/Terpenoids
Trichomes
GLOSSARY
References
icon/caret_left Created with Sketch.

Glossary References

1. Newman MC. Bioaccumulation. Science Direct. 2003
2. Gardener H, Wallin C, Bowen J. Heavy metal and phthalate contamination and labeling integrity in a large sample of US commercially available cannabidiol (CBD) products. Science of The Total Environment. 2022 2022/12/10/;851:158110.
3. NIH. Cannabis (Marijuana) and Cannabinoids: What You Need To Know. Updated November 2019. Accessed October 21, 2022.
4. Hillig KW, Mahlberg PG. A chemotaxonomic analysis of cannabinoid variation in Cannabis (Cannabaceae). Am J Bot. 2004 Jun;91(6):966-75.
5. Establishment of a Domestic Hemp Production Program. In: Department of Agriculture (USDA), editor. 7 CFR: Agricultural Marketing Service.
6. Potter D. The Propagation Characterisation and Optimisation of Cannabis Sativa L as a Phytopharmaceutical. King's College London; 2009.
7. Potter DJ. A review of the cultivation and processing of cannabis (Cannabis sativa L.) for production of prescription medicines in the UK. Drug Test Anal. 2014 Jan-Feb;6(1-2):31-8.
8. Mikos RA, Kam CD. Has the “M” word been framed? Marijuana, cannabis, and public opinion. PLoS One. 2019;14(10):e0224289.
9. Administration UFaD. Remarks by Lowell Schiller, JD at the Council for Responsible Nutrition Conference - 11/7/2019. Accessed October 21, 2022.
10. Mekonnen S. Foxglove-Toxic to the Heart. Accessed October 21, 2022.
11. Rosenberg EC, Tsien RW, Whalley BJ, Devinsky O. Cannabinoids and Epilepsy. Neurotherapeutics. 2015 Oct;12(4):747-68.
12. Ben-Shabat S, Fride E, Sheskin T, et al. An entourage effect: inactive endogenous fatty acid glycerol esters enhance 2-arachidonoyl-glycerol cannabinoid activity. Eur J Pharmacol. 1998 Jul 17;353(1):23-31.
13. Husain R, Weeden H, Bogush D, et al. Enhanced tolerance of industrial hemp (Cannabis sativa L.) plants on abandoned mine land soil leads to overexpression of cannabinoids. PLoS One. 2019;14(8):e0221570.
14. Chaudhary K, Jan S, Khan S. Chapter 23 - Heavy Metal ATPase (HMA2, HMA3, and HMA4) Genes in Hyperaccumulation Mechanism of Heavy Metals. In: Ahmad P, ed. Plant Metal Interaction. Elsevier; 2016:545-556.
15. Brenneisen R. Chemistry and Analysis of Phytocannabinoids and Other Cannabis Constituents. In: ElSohly MA, ed. Marijuana and the Cannabinoids. Humana Press; 2007:17-49.
16. Dayanandan P, Kaufman PB. Trichomes of Cannabis Sativa L. (Cannabaceae). Am J Bot. 1976;63(5):578-591.
17. Bennet P. What are trichomes and why do they exist on cannabis? Updated January 25, 2021. Accessed October 21, 2022.
18. G. Appendino GC, O. Taglialatela-Scafati Cannabinoids: Occurence and Medicinal Chemistry. Current Medicinal Chemistry. 2011;18:1085-1099.
19. Grotenhermen F. Cannabinoids and the Endocannabinoid System. Cannabinoids. 2006 Sept 17;1(1):10 - 14.
20. VanDolah HJ, Bauer BA, Mauck KF. Clinicians' Guide to Cannabidiol and Hemp Oils. Mayo Clin Proc. 2019 Sep;94(9):1840-1851.
21. US Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD). Accessed Dec 3, 2021.
22. Mackie K. Cannabinoid receptors: where they are and what they do. J Neuroendocrinol. 2008 May;20 Suppl 1:10-4.
23. Turner SE, Williams CM, Iversen L, Whalley BJ. Molecular Pharmacology of Phytocannabinoids. Prog Chem Org Nat Prod. 2017;103:61-101.
24. Abioye A, Ayodele O, Marinkovic A, Patidar R, Akinwekomi A, Sanyaolu A. Delta9-Tetrahydrocannabivarin (THCV): a commentary on potential therapeutic benefit for the management of obesity and diabetes. J Cannabis Res. 2020 Jan 31;2(1):6.
25. US Food and Drug Administration. FDA Approves First Drug Comprised of an Active Ingredient Derived from Marijuana to Treat Rare, Severe Forms of Epilepsy.
26. Tahir MN, Shahbazi F, Rondeau-Gagne S, Trant JF. The biosynthesis of the cannabinoids. J Cannabis Res. 2021 Mar 15;3(1):7.
27. US Food and Drug Administration. FDA and Cannabis: Research and Drug Approval Process. Updated Oct 10. Accessed Sept 2, 2021.
28. Hill AJ, Mercier MS, Hill TD, et al. Cannabidivarin is anticonvulsant in mouse and rat. Br J Pharmacol. 2012 Dec;167(8):1629-42.
29. Bolognini D, Rock EM, Cluny NL, et al. Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. Br J Pharmacol. 2013 Mar;168(6):1456-70.
30. Umpierrez LS, Costa PA, Michelutti EA, et al. Cannabidiol but not cannabidiolic acid reduces behavioural sensitisation to methamphetamine in rats, at pharmacologically effective doses. Psychopharmacology (Berl). 2022 May;239(5):1593-1603.
31. Sirikantaramas S, Taura F, Tanaka Y, Ishikawa Y, Morimoto S, Shoyama Y. Tetrahydrocannabinolic acid synthase, the enzyme controlling marijuana psychoactivity, is secreted into the storage cavity of the glandular trichomes. Plant Cell Physiol. 2005 Sep;46(9):1578-82.
32. NIDA. Synthetic Cannabinoids (K2/Spice) DrugFacts. Updated June 2020. Accessed October 21, 2022.
33. Gresoski K. Types of CBD: Full Spectrum vs Broad Spectrum vs Isolate. Hempsley. Accessed Jan 19, 2022.
34. Small E. Hemp: A new crop with New Uses for North America. ASHS Press. 2002:284-326.
35. Section 7606 of 2014 Farm Bill - Legitimacy of Industrial Hemp Research. In: Government US, editor.
36. Justice/DEA Do. Marijuana/Cannabis 2020.
37. Cash MC, Cunnane K, Fan C, Romero-Sandoval EA. Mapping cannabis potency in medical and recreational programs in the United States. PLoS One. 2020;15(3):e0230167-e0230167.
38. Bostwick JM. Blurred boundaries: the therapeutics and politics of medical marijuana. Mayo Clin Proc. 2012 Feb;87(2):172-86.
39. Marijuana Policy Project. “Prescribing” Versus “Recommending” Medical Cannabis. Accessed Dec 3, 2021.
40. US Food and Drug Administration. Inside Clinical Trials: Testing Medical Products in People. Accessed Feb 18, 2022.
41. Hall W. Part 6- Recreational Cannabis: Sough-After Effects, Adverse Effecs, Designer Drugs, and Harm Minimization. Handbook of Cannabis. 2014.
42. Carbonell-Capella JM, Buniowska M, Barba FJ, Esteve MJ, Frigola A. Analytical Methods for Determining Bioavailability and Bioaccessibility of Bioactive Compounds from Fruits and Vegetables: A Review. Compr Rev Food Sci Food Saf. 2014 Mar;13(2):155-171.
43. Dietary Supplement Health and Education Act In: Government US, editor. Public Law 103-417: Congress r.
44. Koch A, Brandenburger S, Türpe S, Birringer M. The Need for a Legal Distinction of Nutraceuticals. Food and Nutrition Sciences. 2014;05(10):905-913.
45. Kalra EK. Nutraceutical--definition and introduction. AAPS PharmSci. 2003;5(3):E25.
46. Gottlieb S. Statement from FDA Commissioner Scott Gottlieb, M.D., on signing of the Agriculture Improvement Act and the agency's regulation of products containing cannabis and cannabis-derived compounds.
47. US Food and Drug Administration. What is a Botanical Drug? FDA.gov. Updated Nov 11, 2021. Accessed Mar 25, 2022.
48. US Drug Enforcement Administration. Drug Scheduling. Accessed Dec 4, 2021.
49. US Food and Drug Administration. Development & Approval Process Drugs. Accessed Dec 5, 2021.
50. Wieten S. Expertise in evidence-based medicine: a tale of three models. Philos Ethics Humanit Med. 2018 Feb 2;13(1):2.
51. Devereaux PJ, Yusuf S. The evolution of the randomized controlled trial and its role in evidence-based decision making. J Intern Med. 2003 Aug;254(2):105-13.
52. Friedman J. The placebo effect. Neurology. 2008;71:e25-e26.
53. Group E-BMW. Evidence-Based Medicine A new approach to teaching the practice of medicine. JAMA. 1992;268(17)
54. Blessing EM, Steenkamp MM, Manzanares J, Marmar CR. Cannabidiol as a Potential Treatment for Anxiety Disorders. Neurotherapeutics. 2015 Oct;12(4):825-36.
55. Akhtar A. The flaws and human harms of animal experimentation. Camb Q Healthc Ethics. 2015 Oct;24(4):407-19.
56. FDA. Sumitting Documents using RWD and RWE to FDA for Drug and Biological Products 2022.


Sponsored by Jazz Pharmaceuticals, Inc.
For further information, please access https://www.jazzpharma.com.
©2023, Jazz Pharmaceuticals, Inc.

Footer menu

  • Privacy Policy
  • Terms Of Use
  • Unsubscribe
  • Update Your Preferences

Sponsored by Jazz Pharmaceuticals, Inc. This website is intended for a US audience.

This site is not intended to provide medical advice or to suggest that any product mentioned is safe or efficacious for any disease or condition.

© Jazz Pharmaceuticals, Inc. All rights reserved. CCL-02498-0323

 
 

Thank you for signing up.
Stay tuned for the latest news and
information about cannabinoids

 

Share These Facts

 

Share via Email